title: [Infections in cystic fibrosis: Up-to-date].
abstract: This review focused on the news in CF airways infection. International guidelines were provided for the care of non tuberculous mycobacteria, and recent studies stressed on the benefit effect of azithromycin or combined antibiotics. The identification of multiresistant environmental bacteria in airways made to account for little-known consequences. Early diagnosis and eradication of Pseudomonas aeruginosa and Staphylococcus aureus methi-R were still a concern, and reports were proposed. However, the studies on staphylococcus methi-R should be interpreted as regards the European or American continent. Thus, levofloxacine has demonstrated its efficacy without enhancing the efficiency. This drug will increase the choice for treating the patient, but no study were provided on the expected modification of the patient microbiota and the known risk of emergent resistance to antibiotics. Lastly, this review underlined that the CF practitioner was encouraged to search and not underestimate the presence of fungus, of which the not so well studied Aspergillus fumigatus.
authors.affiliation: Unité de Pneumologie et Allergologie pédiatrique & CRCM mixte, Département de pédiatrie médicale, Hôpital Universitaire Charles Nicolle, Université de Rouen, France; Groupe de Recherche sur les antimicrobiens et les microorganismes (GRAM-02), UPRES EA 2656, UFR Médecine Pharmacie, Université de Rouen, France. Electronic address: Christophe.marguet@chu-rouen.fr.
authors.forename: C
authors.initials: C
authors.lastname: Marguet
authors.affiliation: Groupe de Recherche sur les antimicrobiens et les microorganismes (GRAM-02), UPRES EA 2656, UFR Médecine Pharmacie, Université de Rouen, France; Département de Microbiologie, Hôpital Universitaire Charles Nicolle, Université de Rouen, France.
authors.forename: L
authors.initials: L
authors.lastname: Lémée
authors.affiliation: CRCM-mixte, Service de pneumologie, Hôpital Universitaire Charles Nicolle, Université de Rouen, France.
authors.forename: H
authors.initials: H
authors.lastname: Morisse-Pradier
authors.affiliation: Unité de Pneumologie et Allergologie pédiatrique & CRCM mixte, Département de pédiatrie médicale, Hôpital Universitaire Charles Nicolle, Université de Rouen, France.
authors.forename: L
authors.initials: L
authors.lastname: Couderc
mesh_terms: D002648:Child; D003550:Cystic Fibrosis / Q000175:diagnosis* / Q000628:therapy*; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D042241:Early Diagnosis; D061345:Early Medical Intervention; D019983:Guideline Adherence; D006801:Humans; D007223:Infant; D064704:Levofloxacin / Q000627:therapeutic use; D009181:Mycoses / Q000175:diagnosis / Q000628:therapy; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000628:therapy*; D012141:Respiratory Tract Infections / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D064704:Levofloxacin